Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652131 | 1.00 | LMNA (0.44) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| SCHEMBL1091147 | 0.69 | MAOA (0.38) | HSD17B10USP2MEN1KMT2A | |
| SCHEMBL338538 | 0.68 | CES1 (0.45) | HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL29417938 | 0.67 | HPGD (0.77) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| SCHEMBL1201517 | 0.67 | HPGD (0.77) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| SCHEMBL2733083 | 0.67 | HPGD (0.77) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| SCHEMBL1201521 | 0.67 | HPGD (0.77) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| SCHEMBL29453066 | 0.67 | HPGD (0.77) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| Hydrochloric Acid SCHEMBL30295054 | 0.65 | HPGD (0.74) | LMNAHSD17B10HPGDL3MBTL1NPSR1 | |
| Water SCHEMBL5462177 | 0.65 | HPGD (0.74) | LMNAHSD17B10HPGDL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | LMNA 3720/4885HSD17B10 3939/4885HPGD 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.